STOCK TITAN
  1. Home
  2. Sec-filings
  3. LH
  4. [8-K] LABCORP HOLDINGS INC. Reports Material Event

Labcorp Holdings Inc. (LH) reshapes lab leadership as Brian Caveney expands role

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Labcorp Holdings Inc. reports a leadership change in its laboratory services business. On August 11, 2026, Megan D. Bailey notified the company of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.

Effective September 1, 2026, Brian J. Caveney, M.D., currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. In this expanded role, he will oversee both the Early Development Research Laboratories and Central Laboratories businesses.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Resignation notice date August 11, 2026 Date Megan D. Bailey notified Labcorp of her decision to resign
Effective date of new role September 1, 2026 Date Brian J. Caveney, M.D. assumes Biopharma Laboratory Services role
Effective resignation date September 4, 2026 Date Megan D. Bailey’s resignation becomes effective
Biopharma Laboratory Services financial
"will assume the role of Executive Vice President and President, Biopharma Laboratory Services"
Central Laboratories financial
"President, Central Laboratories and International of the Company"
Central laboratories are independent, specialized labs that perform the same medical tests and sample analyses for multiple trial sites so results are consistent and comparable across a study. For investors, they matter because reliable, standardized test data reduces the risk of confusing or disputed trial results—think of them as a single referee or quality-control factory that helps confirm whether a treatment is working and therefore influences regulatory decisions and a company’s value.
Early Development Research Laboratories financial
"President, Early Development Research Laboratories and Chief Medical and Scientific Officer"

FAQ

What executive leadership change did Labcorp Holdings Inc. (LH) disclose?
Labcorp disclosed that Megan D. Bailey decided to resign as Executive Vice President and President, Central Laboratories and International. Brian J. Caveney, M.D. will take a new role overseeing Biopharma Laboratory Services.

When is Megan D. Bailey’s resignation from Labcorp (LH) effective?
Megan D. Bailey’s resignation is effective September 4, 2026. She is stepping down from her role as Executive Vice President and President, Central Laboratories and International at Labcorp Holdings Inc.

What new responsibilities will Brian J. Caveney, M.D. assume at Labcorp (LH)?
Effective September 1, 2026, Brian J. Caveney, M.D. will become Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, overseeing Early Development Research Laboratories and Central Laboratories.

Does Labcorp (LH) mention any change to Brian J. Caveney’s Chief Medical and Scientific Officer role?
Labcorp states that Brian J. Caveney, M.D. will continue as Chief Medical and Scientific Officer while assuming the expanded position of Executive Vice President and President, Biopharma Laboratory Services, consolidating oversight of two major laboratory businesses.

What business units will be under Biopharma Laboratory Services at Labcorp (LH)?
Under the new structure, Biopharma Laboratory Services will include responsibility for the company’s Early Development Research Laboratories and Central Laboratories businesses, both overseen by Brian J. Caveney, M.D.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0000920148false00009201482026-08-112026-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

August 11, 2026
(Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107
(State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

358 South Main Street
Burlington,North Carolina27215
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026.
Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.
Registrant


Date: August 14, 2026By:/s/ KATHRYN W. KYLE
Kathryn W. Kyle
Executive Vice President, Chief Legal Officer and Corporate Secretary


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents